Tuesday, November 17, 2015
Print Current Session:
|
|
Tuesday
SESSION 8:
HOW SHOULD MOST PATIENTS WITH UNCOMPLICATED ACUTE TBAD BE TREATED: CONTROVERSY EXISTS AND WILL CONTINUE: THE PROS AND CONS OF EARLY TEVAR
Moderators:Lars G. Svensson, MD, PhD / Santi Trimarchi, MD, PhD
|
|
SESSION 8 SCHEDULE | |
FOR EARLY TEVAR | |
4:48 PM - 4:53 PM | Most Patients With Acute/Subacute Uncomplicated TBADs Should Undergo TEVAR: The INSTEAD-XL RCT Shows Better Long-Term Survival With TEVAR Than With Medical Treatment |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
View Slides in PDF | |
4:54 PM - 4:59 PM | Most Patients With Acute Uncomplicated TBAD Should Receive TEVAR Treatment: I Have Said It Before – Now I Know It Is True And No More Trials Are Needed |
Presenter(s):Rodney A. White, MD | |
5:00 PM - 5:05 PM | Most Patients With Uncomplicated Acute TBAD Should Be Treated By TEVAR: Some Immediately And Some After A 6-12 Week Delay: How Can They Be Selected For Each Based On Data From The MOTHER Registry |
Presenter(s):Matt M. Thompson, MD | |
View Slides in PDF | |
5:06 PM - 5:11 PM | With Uncomplicated Acute TBAD There Is A High Risk Group That Should Be Treated By TEVAR: How Can They Be Selected And When Should They Be Treated |
Presenter(s):Michael D. Dake, MD | |
View Slides in PDF | |
5:12 PM - 5:17 PM | Medical Treatment Is Adequate For Most Patients With Uncomplicated TBAD Based On Current Long-Term Results |
Presenter(s):John A. Elefteriades, MD | |
View Slides in PDF | |
5:18 PM - 5:23 PM | The ADSORB Trial Tells Us What We Need To Know About Treating Uncomplicated TBADs: We Don’t Need Further Trials |
Presenter(s):Jan S. Brunkwall, MD, PhD | |
View Slides in PDF | |
5:24 PM - 5:29 PM | We Still Need More Evidence Before We Treat Most Uncomplicated Acute/Subacute TBAD Patients With TEVAR |
Presenter(s):Michel Makaroun, MD | |
View Slides in PDF | |
5:30 PM - 5:35 PM | Why Wider Use Of TEVAR For Uncomplicated TBADs Right Now May Not Be So Good |
Presenter(s):Frank J. Criado, MD, FACS, FSVM | |
View Slides in PDF | |
5:36 PM - 5:41 PM | The INTACT-AD RCT Comparing TEVAR With Medical Treatment Will Give The Final Answer About The Best Treatment For Uncomplicated Acute/Subacute TBAD Patients: We Need This International Trial And How Will It Be Structured |
Presenter(s):Firas F. Mussa, MD / Christoph A. Nienaber, MD, PhD | |
View Slides in PDF | |
5:42 PM - 5:50 PM | Panel Discussion End of Program A |
END OF SESSION 8 | |
previous | next |